The Washington Post (5/26, McGinley) reports in “To Your Health” that the Food and Drug Administration “on Thursday approved the first implantable drug to deliver long-lasting medication to people addicted to opioids.” The implant, known as Probuphine, “administers the anti-addiction drug buprenorphine in a continuous dose for six months.” It is “intended for people who are already stable on low doses of the drug.” The AP (5/26, Perrone) reports that the “first-of-a-kind device” could “help patients avoid relapses that can… Read More

Increases in Fentanyl Drug Confiscations and Fentanyl-related Overdose Fatalities Summary The Centers for Disease Control and Prevention (CDC) and the Drug Enforcement Administration (DEA) are investigating recent increases in fentanyl-related unintentional overdose fatalities in multiple… Read More

In a world first, the US Food and Drug Administration has given the go-ahead for a 3D-printed pill to be produced: a dissolvable tablet that treats seizures.” Aprecia Pharmaceuticals announced on Monday that the FDA… Read More

Recently, the Drug Enforcement Administration (DEA) issued a final rule rescheduling hydrocodone combination products (HCPs) into Controlled Substance Schedule II, effective October 6, 2014.   Rescheduling issues directly related to Arkansas: Under Arkansas law, physician… Read More

The U.S. Drug Enforcement Administration (DEA) published a final rule Aug. 22 that changes the controlled substance scheduling of hydrocodone combination products (HCP) from Schedule III to Schedule II. The change is scheduled to take effect… Read More

Article below from USA Today Online. Read more at federalregister.gov. WASHINGTON (AP) — The federal government is finalizing new restrictions on hundreds of medicines containing hydrocodone, the highly addictive painkiller that has grown into the… Read More

FDA Acetaminophen Limits in Combination Products   Effective January 14, 2014, it will become unlawful to purchase or sell any narcotic/acetaminophen combination products that contain greater than 325mg of acetaminophen.  This ban on high dosage acetaminophen… Read More

The Wall Street Journal (7/27, Burton, Subscription Publication, 2.29M) reported that the US Food and Drug Administration announced Friday that it was limiting the use of Johnson & Johnson’s oral, anti-fungal therapy, Nizoral (ketoconazole). Although… Read More

An important FDA-approved Drug Alert for INVIRASE affecting Cardiology, Infectious Disease, Internal Medicine, Pediatrics, Nurse Practitioners, and Pharmacies was published on February 28, 2013. This PDR® Drug Alert was delivered electronically to all Arkansas Medical… Read More

An important FDA-approved Drug Alert for XELJANZ affecting Rheumatologists, Infectious Disease, Family Medicine/General Practice, Internal Medicine and  Emergency Medicine physicians was published on November 20, 2012. This PDR® Drug Alert was delivered electronically to all… Read More

An important FDA-approved Drug Alert for BONIVA affecting Family Medicine/General Practitioners, Internal Medicine, Endocrinology, Diabetes & Metabolism and Obstetrics & Gynecology was published on October 1, 2012. This PDR® Drug Alert was delivered electronically to… Read More